141 related articles for article (PubMed ID: 38668876)
1. Comprehensive analysis and prognostic assessment of senescence-associated genes in bladder cancer.
Yang R; He J; Luo W; Xiang R; Zou G; Zhang X; Liu H; Deng J
Discov Oncol; 2024 Apr; 15(1):130. PubMed ID: 38668876
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
5. A novel anoikis-related gene signature identifies LYPD1 as a novel therapy target for bladder cancer.
Song Z; Gui S; Xiao S; Rao X; Cong N; Deng H; Yu Z; Zeng T
Sci Rep; 2024 Feb; 14(1):3198. PubMed ID: 38332160
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
7. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
8. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
9. Deciphering the significance of anoikis in bladder cancer and systematic analysis of S100A7 as a potential therapeutic target.
Wang H; Liu J; Tang R; Hu J; Liu M; Wang J; Zhang J; Hou H
Eur J Med Res; 2024 Jan; 29(1):52. PubMed ID: 38217031
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
11. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
Front Genet; 2021; 12():696912. PubMed ID: 34512722
[No Abstract] [Full Text] [Related]
12. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
Hu J; Wang L; Li L; Wang Y; Bi J
BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
[TBL] [Abstract][Full Text] [Related]
13. Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma.
Xu C; Pei D; Liu Y; Yu Y; Guo J; Liu N; Kang Z
Front Oncol; 2022; 12():818860. PubMed ID: 35299749
[TBL] [Abstract][Full Text] [Related]
14. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
15. Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer.
Xu C; Song L; Peng H; Yang Y; Liu Y; Pei D; Guo J; Liu N; Liu J; Li X; Li C; Kang Z
Front Mol Biosci; 2022; 9():963455. PubMed ID: 35936781
[No Abstract] [Full Text] [Related]
16. The construction and validation of an RNA binding protein-related prognostic model for bladder cancer.
Chen F; Wang Q; Zhou Y
BMC Cancer; 2021 Mar; 21(1):244. PubMed ID: 33685397
[TBL] [Abstract][Full Text] [Related]
17. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
18. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Li Z; Li Y; Liu L; Zhang C; Li X
Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
[TBL] [Abstract][Full Text] [Related]
19. Identification of clinical prognostic factors and analysis of ferroptosis-related gene signatures in the bladder cancer immune microenvironment.
Ma J; Hu J; Zhao L; Wu Z; Li R; Deng W
BMC Urol; 2024 Jan; 24(1):6. PubMed ID: 38172792
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of an Individualized Prognostic Signature of Bladder Cancer Based on Seven Immune Related Genes.
Qiu H; Hu X; He C; Yu B; Li Y; Li J
Front Genet; 2020; 11():12. PubMed ID: 32117435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
